MX2019006942A - Agonistas de receptores de oxitocina no peptidicos. - Google Patents
Agonistas de receptores de oxitocina no peptidicos.Info
- Publication number
- MX2019006942A MX2019006942A MX2019006942A MX2019006942A MX2019006942A MX 2019006942 A MX2019006942 A MX 2019006942A MX 2019006942 A MX2019006942 A MX 2019006942A MX 2019006942 A MX2019006942 A MX 2019006942A MX 2019006942 A MX2019006942 A MX 2019006942A
- Authority
- MX
- Mexico
- Prior art keywords
- formula
- receptor agonists
- compounds
- oxytocin receptor
- pharmaceutically acceptable
- Prior art date
Links
- 102000004279 Oxytocin receptors Human genes 0.000 title 1
- 108090000876 Oxytocin receptors Proteins 0.000 title 1
- 239000000018 receptor agonist Substances 0.000 title 1
- 229940044601 receptor agonist Drugs 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 5
- 238000000034 method Methods 0.000 abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 abstract 2
- 239000003085 diluting agent Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 239000003937 drug carrier Substances 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 239000000546 pharmaceutical excipient Substances 0.000 abstract 1
- 208000020016 psychiatric disease Diseases 0.000 abstract 1
- 230000011273 social behavior Effects 0.000 abstract 1
- 208000011117 substance-related disease Diseases 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Psychiatry (AREA)
- Addiction (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Pyridine Compounds (AREA)
Abstract
En este documento se dan a conocer compuestos de acuerdo con la Fórmula I, y una composición farmacéutica que incluye, consiste esencialmente o consiste en: un compuesto farmacéuticamente aceptable de la Fórmula I y un portador, diluyente o excipiente farmacéuticamente aceptable, el uso de los compuestos de la Fórmula I en la preparación de un medicamento, y un método que incluye administrar una composición farmacéutica que comprende el compuesto de la Fórmula I a un paciente. Los compuestos, composiciones, uso y métodos se dirigen al tratamiento de trastornos psiquiátricos neurológicos que se caracterizan por una desestabilización fundamental del comportamiento social, y de trastornos por el uso de sustancias.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2016905126A AU2016905126A0 (en) | 2016-12-12 | Non-peptide oxytocin receptor agonists | |
| PCT/AU2017/051371 WO2018107216A1 (en) | 2016-12-12 | 2017-12-12 | Non-peptide oxytocin receptor agonists |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2019006942A true MX2019006942A (es) | 2019-10-21 |
Family
ID=62557695
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2019006942A MX2019006942A (es) | 2016-12-12 | 2017-12-12 | Agonistas de receptores de oxitocina no peptidicos. |
Country Status (19)
| Country | Link |
|---|---|
| US (2) | US11491165B2 (es) |
| EP (2) | EP3551631B9 (es) |
| JP (3) | JP7089649B2 (es) |
| KR (1) | KR102561721B1 (es) |
| CN (1) | CN110248944A (es) |
| AU (1) | AU2017377653B2 (es) |
| BR (1) | BR112019012049A2 (es) |
| CA (1) | CA3046809A1 (es) |
| DK (1) | DK3551631T3 (es) |
| ES (1) | ES3001195T3 (es) |
| FI (1) | FI3551631T3 (es) |
| HU (1) | HUE070078T2 (es) |
| IL (1) | IL267276B2 (es) |
| MX (1) | MX2019006942A (es) |
| PL (1) | PL3551631T3 (es) |
| PT (1) | PT3551631T (es) |
| RU (1) | RU2019120162A (es) |
| SI (1) | SI3551631T1 (es) |
| WO (1) | WO2018107216A1 (es) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU2019383052A1 (en) * | 2018-11-23 | 2021-06-10 | Macquarie University | Methods for management of weight |
| US20220288060A1 (en) * | 2019-09-06 | 2022-09-15 | Kinoxis Therapeutics Pty Ltd | Treatment of Opioid Withdrawal |
| EP4028016A1 (en) | 2019-09-13 | 2022-07-20 | Origenis GmbH | 1,4-dihydrobenzo[d]pyrazolo[3,4-f][1,3]diazepine derivatives and related compounds as lrrk2, nuak1 and/or tyk2 kinase modulators for the treatment of e.g. autoimmune disease |
| MX2023006986A (es) * | 2020-12-14 | 2023-06-26 | Kinoxis Therapeutics Pty Ltd | Moduladores de receptor de oxitocina. |
| BR112023018741A2 (pt) * | 2021-03-18 | 2023-10-24 | Kinoxis Therapeutics Pty Ltd | Métodos de tratamento |
Family Cites Families (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3770762A (en) * | 1972-08-29 | 1973-11-06 | Parke Davis & Co | Diazepine compounds and methods for their production |
| AR002459A1 (es) * | 1995-01-17 | 1998-03-25 | American Cyanamid Co | Antagonistas de vasopresina de benzacepina triciclicos, una composicion farmaceutica que los contiene, un metodo para tratar enfermedades y unprocedimiento para su preparacion. |
| US5536718A (en) * | 1995-01-17 | 1996-07-16 | American Cyanamid Company | Tricyclic benzazepine vasopressin antagonists |
| GB0115515D0 (en) * | 2001-06-25 | 2001-08-15 | Ferring Bv | Oxytocin agonisys |
| GB0120051D0 (en) | 2001-08-16 | 2001-10-10 | Ferring Bv | Oxytocin agonists |
| EP1449844A1 (en) | 2003-02-14 | 2004-08-25 | Ferring B.V. | benzamide derivatives as oxytocin agonists and vasopressin antagonists |
| US7342112B2 (en) * | 2003-07-01 | 2008-03-11 | Ppg Industries Ohio, Inc. | Photochromic compounds |
| EP1512687A1 (en) * | 2003-09-05 | 2005-03-09 | Ferring B.V. | Piperazines as oxytocin agonists |
| EP1632494A1 (en) * | 2004-08-24 | 2006-03-08 | Ferring B.V. | Vasopressin v1a antagonists |
| AU2005293818A1 (en) * | 2004-10-13 | 2006-04-20 | F. Hoffmann-La Roche Ag | Disubstituted pyrazolobenzodiazepines useful as inhibitors for CDK2 and angiogesis, and for the treatment of breast, colon, lung and prostate cancer |
| CN101203516A (zh) * | 2005-04-05 | 2008-06-18 | 法马科皮亚公司 | 用于免疫抑制的嘌呤及咪唑并吡啶衍生物 |
| RU2008114374A (ru) | 2005-10-24 | 2009-12-10 | Вайет (Us) | Трициклические соединения, применяемые в качестве агонистов рецептора окситоцина |
| WO2008103367A2 (en) * | 2007-02-20 | 2008-08-28 | Sergey Kozmin | Method for assembling high-purity chemical libraries, proapoptotic compounds discovered by same |
| GB0903493D0 (en) * | 2009-02-27 | 2009-04-08 | Vantia Ltd | New compounds |
| WO2016089830A1 (en) * | 2014-12-05 | 2016-06-09 | Merck Sharp & Dohme Corp. | Novel tricyclic compounds as inhibitors of mutant idh enzymes |
| AU2016289271B2 (en) * | 2015-07-06 | 2020-12-03 | Kinoxis Therapeutics Pty Ltd | Therapeutic compounds and compositions for treating social disorders and substance use disorders |
-
2017
- 2017-12-12 PT PT178800827T patent/PT3551631T/pt unknown
- 2017-12-12 CN CN201780085825.XA patent/CN110248944A/zh active Pending
- 2017-12-12 IL IL267276A patent/IL267276B2/en unknown
- 2017-12-12 ES ES17880082T patent/ES3001195T3/es active Active
- 2017-12-12 DK DK17880082.7T patent/DK3551631T3/da active
- 2017-12-12 BR BR112019012049-1A patent/BR112019012049A2/pt active Search and Examination
- 2017-12-12 JP JP2019531447A patent/JP7089649B2/ja active Active
- 2017-12-12 MX MX2019006942A patent/MX2019006942A/es unknown
- 2017-12-12 FI FIEP17880082.7T patent/FI3551631T3/fi active
- 2017-12-12 KR KR1020197019977A patent/KR102561721B1/ko active Active
- 2017-12-12 WO PCT/AU2017/051371 patent/WO2018107216A1/en not_active Ceased
- 2017-12-12 EP EP17880082.7A patent/EP3551631B9/en active Active
- 2017-12-12 RU RU2019120162A patent/RU2019120162A/ru unknown
- 2017-12-12 AU AU2017377653A patent/AU2017377653B2/en active Active
- 2017-12-12 EP EP24212001.2A patent/EP4494705A3/en active Pending
- 2017-12-12 CA CA3046809A patent/CA3046809A1/en active Pending
- 2017-12-12 SI SI201731588T patent/SI3551631T1/sl unknown
- 2017-12-12 PL PL17880082.7T patent/PL3551631T3/pl unknown
- 2017-12-12 HU HUE17880082A patent/HUE070078T2/hu unknown
-
2019
- 2019-06-12 US US16/439,570 patent/US11491165B2/en active Active
-
2022
- 2022-05-11 JP JP2022078250A patent/JP2022097655A/ja active Pending
- 2022-09-16 US US17/932,914 patent/US20230330103A1/en active Pending
-
2024
- 2024-06-05 JP JP2024091625A patent/JP2024107136A/ja active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| ZA202500997B (en) | Benzoxazepin oxazolidinone compounds and methods of use | |
| PH12020551870A1 (en) | Tetracyclic heteroaryl compounds | |
| MX2021007432A (es) | Compuestos y composiciones para inhibir la actividad de shp2. | |
| MX393395B (es) | Derivado de heteroaril[4,3-c]pirimidina-5-amina, método de preparación del mismo y usos médicos del mismo. | |
| CY1119490T1 (el) | Παραγωγα πυραζολοπυρρολιδινης και η χρηση τους στην θεραπεια νοσηματων | |
| MX2020010151A (es) | Analogos de piridazina 1,4-disustituida y metodos para el tratamiento de condiciones relacionadas con la deficiencia de smn. | |
| EA033544B1 (ru) | Производные пиридона в качестве ингибиторов киназы, реаранжированной во время трансфекции (ret) | |
| MY192354A (en) | 4-imidazopyridazin-1-yl-benzamides and 4-imidazotriazin-1-yl-benzamides as btk-inhibitors | |
| MD20140059A2 (en) | Substituted 4-phenyl-pyridines for the treatment of NK-1 receptor related diseases | |
| MX2015016344A (es) | Derivados de imidazo-pirrolidinona y su uso en el tratamiento de enfermedades. | |
| MX2017007814A (es) | Compuesto de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| MX2015008975A (es) | Analogos de tiadiazol y metodos para el tratamiento de afecciones relacionadas con deficiencia del gen de supervivencia de las neuronas motoras (smn). | |
| MX2017012393A (es) | Compuestos de carbamoilpiridona policiclicos y su uso farmaceutico. | |
| MX351305B (es) | Antagonistas del receptor de mineralocorticoides. | |
| PH12016502103A1 (en) | Novel disubstituted 1,2, 4-triazine compound | |
| MX2013012588A (es) | Inhibidores de cinasa. | |
| MX2015010829A (es) | Compuestos terapeuticos y sus usos. | |
| GEP20166483B (en) | Phenyl-3-aza-bicyclo[3.1.0] hex-3-yl-methanones and the use thereof as medicament | |
| MX2019006942A (es) | Agonistas de receptores de oxitocina no peptidicos. | |
| HK1217092A1 (zh) | 治疗性化合物及其用途 | |
| PH12018501285A1 (en) | Alkyl dihydroquinoline sulfonamide compounds | |
| UA117154C2 (uk) | Антагоністи s1p3 | |
| MX2017013099A (es) | Metodos para el tratamiento de trastornos inflamatorios. | |
| EA201691920A1 (ru) | Новые конденсированные соединения имидазобензотиазола | |
| MX2018015990A (es) | Compuestos terapeuticos. |